Theradiag: Report of the Extraordinary General Meeting on Second Call of June 10, 2021
10 Giugno 2021 - 5:45PM
Business Wire
Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for
PEA-PME equity savings plans), a company specializing in in
vitro diagnostics and theranostics, announces that the
Extraordinary General Meeting held today in camera on 2nd
convocation was able to validly deliberate. The quorum was reached,
with 20.87% of the voting rights represented.
The shareholders of the Company adopted the twenty-first and
twenty-second resolutions of the extraordinary general meeting, the
remaining resolutions were rejected. All of these resolutions can
be consulted in the presentation of the general meeting of June 10,
2021 available on Theradiag's website in the General Meetings
section.
Given the constraints related to the COVID-19 context,
Theradiag's general meeting was held in camera and was broadcast
live on the Internet. A replay will be available on the Company's
website in the General Meetings section. The minutes of the meeting
will also be available within the legal deadlines in the General
Meetings section.
Financial calendar: - H1 2021 revenue, on Monday
July 19, 2021 - H1 2021 results, on Monday September 20,
2021
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing, and marketing
innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210610005660/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024